愛康醫療(01789.HK)向81名合資格參與者授出合共171萬股獎勵股份
格隆匯7月15日丨愛康醫療(01789.HK)公吿,於2024年7月15日,公司根據股份獎勵計劃的條款向81名合資格參與者授出合共1,706,959股獎勵股份,其中一名合資格參與者為執行董事及其餘80名合資格參與者為集團僱員。所有1,706,959股獎勵股份均以零代價授出,並將以受託人持有的現有已發行股份支付。
董事會認為,上述授出是為了(i)肯定承授人過去對集團的貢獻;(ii)使承授人的利益與集團的利益一致;及(iii)就承授人對集團的長期增長及成功作出貢獻鼓勵及挽留承授人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.